Spray cryotherapy for palliation of locally advanced adenocarcinoma in Barrett's esophagus.

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 152-152
Author(s):  
C. Lin ◽  
D. Kerstetter ◽  
F. Habr

152 Background: Up to 60% of patients with esophageal cancer are deemed inoperable at the time of diagnosis due to either advanced stage or significant co-morbidities. Currently, endoscopic palliative measures include stenting and photodynamic therapy. Although spray cryotherapy has been successfully used in ablating Barrett's esophagus, and different grades of dysplasia, there has been only one published case describing complete remission of squamous cell carcinoma following cryoablation. We present the first case of the use of the CryoSpray Ablation System (CSA Medical, Baltimore, MD) for palliative treatment of an esophageal T3 adenocarcinoma in an elderly woman with dysphagia and weight loss. Methods: An upper endoscopy was performed with standard monitored anesthesia. A special dual lumen Cryo decompression tube is introduced over an endoscopically placed savary guidewire in the gastric antrum and connected to suction. This tube is used to decompress the stomach when the liquid nitrogen is sprayed. Cryoablation is performed using the CryoSpray Ablation System that uses liquid nitrogen is delivered via a 7 Fr catheter at low pressures (2-3 PSI) at -196°C.The lesion was treated with four freeze cycles of 10-20 seconds each with 60 second interim thaws. Freezing and thawing techniques were monitored by direct visualization. The procedure is repeated every 4-6 weeks. The patient received a total of 7 treatments over 10 months. Results: The patient did not experience any adverse effects after treatment. After 3 treatments (week 20), complete endoscopic resolution of the lesion was noted, with regression of the Barrett's mucosa and major improvement of her dysphagia. At week 28, a recurrent mass was seen on EGD in the mid-esophagus. This was treated with 3 sessions of spray cryotherapy at 4 week intervals with improvement of dysphagia after each application. 11 months after her initial cryotherapy, the patient opted to have an esophageal stent due to tumor progression. Conclusions: Spray cryotherapy is a safe and effective endoscopic modality for the ablation of Barrett's esophagus and superficial esophageal cancer, it is a promising new modality for the palliation of advanced esophageal cancer. No significant financial relationships to disclose.

2007 ◽  
Vol 14 (8) ◽  
pp. 2406-2410 ◽  
Author(s):  
Samuel B. Keeley ◽  
Arjun Pennathur ◽  
William Gooding ◽  
Rodney J. Landreneau ◽  
Neil A. Christie ◽  
...  

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 9-9
Author(s):  
M. C. Stauder ◽  
Y. Romero ◽  
B. Kabat ◽  
P. J. Atherton ◽  
M. B. Fredericksen ◽  
...  

9 Background: We examined patient-reported fatigue scores and overall survival (OS) in patients with esophageal cancer (EC) enrolled in the Mayo Clinic Esophageal Adenocarcinoma and Barrett's Esophagus Registry (EABE). Methods: 1,481 patients enrolled in the EABE between September 2001 and January 2009 returned a baseline quality of life questionnaire including a Linear Analog Self Assessment (LASA) fatigue score which was scored on a 0-10 scale, with 0 as the most extreme fatigue. Patients were categorized as having clinically deficient fatigue (DF) if they reported a score of ≤ 5 and clinically non-deficient fatigue (nDF) if they reported a score of > 5. Kaplan-Meier methodology and Cox models explored OS in relation to fatigue scores in patients with EC. Results: A total of 667 patients with EC were included in the EABE, of which 659 returned a registry questionnaire with a valid LASA fatigue score recorded. Median age at the time of registry entry was 65 years (range 23-92). A total of 392 (59%) and 267 patients (41%) reported DF and nDF, respectively. On univariate analysis, patients with nDF had improved 5-year survival compared to patients with DF. In patients having esophagectomy prior to LASA, those reporting nDF had improved survival compared to patients with DF. Similarly, in patients having no esophagectomy prior to LASA, those with nDF had improved survival compared to those with DF. Among the 368 patients with locally advanced EC (LAEC), those reporting nDF had improved 5-year overall survival compared to patients with DF (28% vs 17%, HR = 0.67, p = 0.003). This remained significant on multivariate analysis (HR = 0.71, p = 0.015). Conclusions: Patient-reported fatigue is associated with overall survival in patients with LAEC. As a result, fatigue scores should be considered as a stratification factor in future clinical trial design. [Table: see text] No significant financial relationships to disclose.


2018 ◽  
pp. 39-50
Author(s):  
Jean Marc Chevallier ◽  
Sonja Chiappetta ◽  
Mario Musella

2013 ◽  
Vol 58 (11) ◽  
pp. 3178-3188 ◽  
Author(s):  
Katherine S. Garman ◽  
Kouros Owzar ◽  
Elizabeth R. Hauser ◽  
Kristen Westfall ◽  
Blair R. Anderson ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document